Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2000
11/21/2000US6150101 Methods of identifying a composition that alters connective tissue growth factor expression
11/21/2000US6150093 Unique associated Kaposi's sarcoma virus sequences and uses thereof
11/21/2000US6150087 Non-hepatitis a or b virus polypeptide which is capable of illiciting immune response with hepatitus virus antibodies, for the treatment of and prevention of viral infections
11/21/2000US6149922 Vaccine adjuvant and vaccine
11/21/2000US6149921 An immunogen is coupled to a carrier protein comprising the outer membrane protein complex of neisseria meningitidis, by non-covalent hydrophobic interaction; treatment of breast cancers
11/21/2000US6149920 Vaccine for immunization, prophylaxis or treatment of a vertebrate at risk of or suffering from brucellosis, wherein said vaccine comprises an attenuated or avirulent strain of an otherwise pathogenic bacteria of the genus brucella
11/21/2000US6149919 Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines
11/21/2000US6149918 The cell line contains a human herpesvirus type 8 virus particle and does not contain epstein barr virus; for the production of antibodies or screening a biological sample of the human suspected of being infected with virus
11/21/2000US6149917 Culturing, inoculating the cells with japanese encephalitis virus, propagating and multiplying the virus, harvesting, purifying viruses by ion-exchange chromatographic process, adsorption chromatography and gel permeation
11/21/2000US6149911 Method for enhancing the immunogenicity of an immunogenic compound or hapten, and use thereof for preparing vaccines
11/21/2000US6149905 Administering a modifying tumor cells from a mammalian subject to express a b7 molecule; preventing or inhibiting metastatic spread of a tumor
11/21/2000US6149902 Manipulation of non-terminally differentiated cells using the notch pathway
11/21/2000US6149671 Laser/sensitizer assisted immunotherapy
11/21/2000CA2159452C Needleless syringe using supersonic gas flow for particle delivery
11/21/2000CA2081482C Method and composition for treatment of central nervous system disease states associated with abnormal amyloid beta protein molecular organization
11/21/2000CA2038578C Delivery of agents
11/16/2000WO2000068430A1 Rnase p polypeptides, polynucleotides, and methods using their mechanisms of action
11/16/2000WO2000068392A1 Plant-derived antigens against respiratory syncytial virus
11/16/2000WO2000068384A2 NOVEL NUCLEIC ACIDS AND PROTEINS WITH p53 ACTIVITY AND ALTERED TETRAMERIZATION DOMAINS
11/16/2000WO2000068261A2 Attenuated microorganisms for the treatment of infection
11/16/2000WO2000068259A2 Vaccine
11/16/2000WO2000068243A1 Methods using mechanisms of action of aroa
11/16/2000WO2000068242A1 Collagen-binding proteins from enterococcal bacteria
11/16/2000WO2000068240A1 NOVEL aroA
11/16/2000WO2000067796A1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/16/2000WO2000067795A1 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
11/16/2000WO2000067793A1 Death domain containing receptor 4
11/16/2000WO2000067792A1 Monoclonal antibody directed against cells of human renal cell carcinoma
11/16/2000WO2000067791A1 Ccr4 antagonists in sepsis
11/16/2000WO2000067789A1 High concentration immunoglobulin preparation and method for its production
11/16/2000WO2000067788A2 Use of soluble costimulatory molecules to enhance immune responses
11/16/2000WO2000067787A2 Hiv immunogenic compositions and methods
11/16/2000WO2000067786A1 PRODUCTION OF NOVEL NEWCASTLE DISEASE VIRUS STRAINS FROM cDNAS AND IMPROVED LIVE ATTENUATED NEWCASTLE DISEASE VACCINES
11/16/2000WO2000067785A2 Staphyloccocus aureus antigen-containing whole cell vaccine
11/16/2000WO2000067784A1 Bacteriophage isolated from bacterial genomes and extrachromosomal elements and methods of use thereof
11/16/2000WO2000067761A1 Compositions and methods for identifying antigens which elicit an immune response
11/16/2000WO2000067700A2 Recombinant vaccine against botulinum neurotoxin
11/16/2000WO2000053633A3 Antibody and chemokine constructs that are directed to ccr5, and their use for treating autoimmune diseases
11/16/2000WO2000047223A3 Viral vaccine
11/16/2000WO2000044406A3 Dna vaccines against hantavirus infections
11/16/2000WO2000044389A3 Method for preparing membrane vesicles
11/16/2000WO2000042191A3 Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
11/16/2000WO2000042179A3 Complex-forming proteins
11/16/2000WO2000041717A3 Chorionic gonadotropin dna vaccines and methods
11/16/2000WO2000039287A3 A. fumigatus acetyl coenzyme-a carboxylase genes and polypeptides and uses thereof
11/16/2000WO2000038665A3 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
11/16/2000WO2000037613A3 Human akt-3
11/16/2000WO2000037025A3 Antibodies to truncated vegf-d and uses thereof
11/16/2000WO2000034468A3 Muc-1 antagonists and methods of treating immune disorders
11/16/2000WO2000033874B1 Boron neutron capture therapy using pre-targeting methods
11/16/2000WO2000029561A3 Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
11/16/2000WO2000029015A3 INFLUENCING OF ANGIGENESIS USING CD66a
11/16/2000WO2000020448A3 Nlk1 -interacting proteins
11/16/2000WO2000007631A9 Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
11/16/2000WO1999066025A3 Mtbx protein and nucleic acid molecules and uses therefor
11/16/2000DE19922407A1 Preparing medicament for treating viral infections, liver diseases or cancer, comprising recombinant parapoxvirus targeted towards specific organs, cells or tissues
11/16/2000DE19919225A1 Tumorassoziiertes Antigen Tumor-associated antigen
11/16/2000CA2503110A1 Collagen-binding proteins from enterococcal bacteria
11/16/2000CA2374237A1 Compositions and methods for identifying antigens which elicit an immune response
11/16/2000CA2373631A1 Monoclonal antibody directed against cells of human renal cell carcinoma
11/16/2000CA2373618A1 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
11/16/2000CA2373256A1 Use of soluble costimulatory molecules to enhance immune responses
11/16/2000CA2373063A1 Death domain containing receptor 4
11/16/2000CA2372881A1 Novel nucleic acids and proteins with p53 activity and altered tetramerization domains
11/16/2000CA2372497A1 Vaccine composition comprising r28 protein of streptococcus pyogenes
11/16/2000CA2371279A1 Recombinant vaccine against botulinum neurotoxin
11/15/2000EP1052285A2 Method of inducing an antigen-specific anticytotoxic cell
11/15/2000EP1051620A1 Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha
11/15/2000EP1051507A1 Antigen-specific cells, methods of generating these cells and uses thereof
11/15/2000EP1051500A2 Diagnosis and treatment of aur1 and/or aur2 related disorders
11/15/2000EP1051494A1 Methods and reagents for decreasing allergic reactions
11/15/2000EP1051489A2 Compounds for therapy and diagnosis of lung cancer and methods for their use
11/15/2000EP1051488A2 Human growth factor homologs
11/15/2000EP1051483A1 A method of isolating a peptide which immunologically mimics microbial carbohydrates including group b streptococcal carbohydrates and the use thereof
11/15/2000EP1051482A1 Cytotoxic heteromeric protein combinatorial libraries
11/15/2000EP1051192A2 Methods for the prevention and treatment of fibrosis and sclerosis
11/15/2000EP1051191A2 Cd154 blockade therapy for pancreatic islet tissue transplantation
11/15/2000EP1051190A1 Vaccine compositions for mucosal administration comprising chitosan
11/15/2000EP1051189A2 Vaccine formulations
11/15/2000EP1051187A1 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
11/15/2000EP0765343B1 MONOCLONAL ANTIBODY ACTIVE AGAINST CD44v6
11/15/2000EP0658168B1 Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
11/15/2000EP0650371B1 Covalent polar lipid-peptide conjugates for biological targeting
11/15/2000CN1273603A Attenuated respiratory syncytial viruses
11/15/2000CN1273588A Amino acid sequences for therapeutical and prophylacticapplications to disedses due to i (clostridium difficile) toxinc
11/15/2000CN1273127A Genetically engineered body for preparing somatostatin subunit vaccine
11/15/2000CN1058522C New strain of ribrio comma and its live vaccine
11/15/2000CN1058411C High-grade lift-prolonging health oral liquid
11/14/2000US6147203 Recombinant disulfide-stabilized polypeptide fragments having binding specificity
11/14/2000US6147201 Nucleotide sequences coding acarnia protein; for the diagnosis and treatment of sensitivity to acarnia allergy proteins
11/14/2000US6147190 Protein associated with activating cell propagation; for the treatment of a nervous system disorders; for diagnosis and treatment of tumors; antitumor agents
11/14/2000US6147187 Major histocompatibility complex proteins; for diagnosis and treatment of tumors; antitumor agents
11/14/2000US6147057 Immunogenic composition
11/14/2000US6146902 Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
11/14/2000US6146873 Growing continuous culture of monkey kidney cells for more than one generation in protein-free media, infecting with virus, selecting for desired phenotype, and isolating virus; for influenza vaccine
11/14/2000US6146870 Flea protease proteins
11/14/2000US6146863 Staphylococcus aureus 3-hydroxyacyl-CoA dehydrogenase
11/14/2000US6146846 Primosome protein a of streptococcus pneumoniae
11/14/2000US6146845 Polynucleotides encoding a sialoadhesin family member-2 (SAF-2)
11/14/2000US6146837 Detecting fc gamma receptor (cd64) in a biological sample by conacting sample with cyanin compound, cy5; illuminating the sample with light of an appropriate excitation wavelength; and detecting fluorescence
1 ... 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 ... 1823